| |
 |
 |  |  |  |  |  |  |  |
 |
|
|||||||||
公司新闻 | ||||||||||
|
||||||||||
<< 回到上页美国新资投资银行与硅谷纳米技术创投机构建立战略联盟关系August 15, 2005 - Los Angeles, CA - NewCap Partners Inc., a Los Angeles based investment banking firm, announced today that it has entered into a strategic alliance with Silicon Valley Nano Ventures to focus on companies in the nanotechnology industry. Silicon Valley Nano Ventures delivers start-up and early-stage angel, corporate, and venture capitalist funding to nanotechnology companies focused on biotechnology, electronics, materials, sensors, semiconductor, software, tools, and photonics applications. With the alliance, NewCap Partners and Silicon Valley Nano Ventures are combining strategic consulting and investment banking skills to provide clients with a unique combination of services.
"Our focus on start-up and early-stage funding, joint ventures, strategic consulting, and affiliation network marketing together with the later stage strategic merger and acquisition capabilities of NewCap Partners enables us to offer our clients a seamless transition from technology innovation to later stage funding and liquidity, " according to Bo Varga, Managing Director, Silicon Valley Nano Ventures. "We see significant synergy between the 6,500 consultants, entrepreneurs, executives, government employees, investors, and researchers in our nanotechnology people database and the wide range of corporate and funding people in the NewCap business network.
NewCap Partners and Silicon Valley Nano Ventures believe that there will be an increasing focus on merger and acquisition transactions for nanotechnology companies in the foreseeable future due to the limited financing in the public and private equity capital markets for start-up and early-stage nanotechnology companies, and that the combination of the skills of the two organizations are a great match for clients. "Nanotechnology is one of the industries on which we are focused and our relationship with Silicon Valley Nano Ventures allows us to couple our finance and investment banking skills with their global people network and industry knowledge. Bo Varga staged over 60 global conferences, forums, and seminars in the past 5 years to introduce start-up and early-stage projects to investors and we are pleased to work with him," said Kenneth A. Epstein, Principal of NewCap Partners, who also has global nanotech experience.
About NewCap Partners, Inc.
NewCap Partners, Inc., founded in 1987, is a private investment banking firm located in Los Angeles, California, (USA) with offices in Orange County and Silicon Valley. NewCap Partners provides specialized strategic merger, acquisition and divestiture services to buyers and sellers. NewCap Partners also privately places debt and equity securities for its clients to finance expansion, acquisitions, buyouts, recapitalizations and reorganizations. NewCap Partners also specializes in business transactions in the Greater China Region. NewCap Partners is staffed by a team of senior, experienced and professional investment bankers. For additional information on NewCap Partners visit our website at www.newcap.com.
About Silicon Valley Nano Ventures
Founded by Bo Varga in 2000, Silicon Valley Nano Ventures specializes in providing start-up and early-stage nanotechnology companies with the three key requirements to build a business - customers, money and people. Services include strategic consulting, with emphasis on building business models and presentations, and on affiliation network and event marketing, with emphasis on leveraging marketing to enable customer, money, or people transactions. For additional information on Silicon Valley Nano Ventures visit the website at www.USnano.biz
CONTACTS:
GNI公司与上海睿星合并日本的生物科技与中国的生物科技公司合并以增强研发能力并增加市场机会TOKYO and SHANGHAI, June 20, 2005 GNI Ltd. and Shanghai Genomics announced today that the two companies have completed a merger. NewCap Partners, Inc. (www.newcap.com) served as Shanghai Genomics' investment advisor for the transaction. GNI concurrently raised a private equity round of financing of over $13M led by Nomura, Healthcare Partners and several other U.S. and Japanese private equity firms. The merger delivers several benefits, most notably from Shanghai Genomics' Western-quality discovery research, preclinical development, and contract research services to facilitate cost-efficient drug development, faster revenue generation and, ultimately, profitability for the united company. Moreover, the merger will combine drug development technologies that will streamline GNI's discovery, preclinical and clinical programs. GNI will also leverage U.K. and Japanese derived, high-value drug targets and molecules and benefit from the efficiency and speed of Chinese preclinical and clinical development. The combined company will have a research staff of over 80 employees (20 Ph.D.) in Japan, China and the United Kingdom, several drug candidates in clinical and pre-clinical development, and rapidly growing collaboration revenues from U.S., European and Japanese pharmaceutical companies outsourcing biological R&D to China. Dr. Christopher Savoie will serve as CEO of GNI, Dr. Ying Luo as the Company's President, and Dr. Jun Wu will become CSO. Both Luo and Wu will join the GNI board. "GNI has the right business and financial model for Asian life sciences at the right time," said Richard Parkinson, a principal with Healthcare Partners. "With its combined technology, clinical development, growing collaboration revenues and access to the Japanese financial markets we expect GNI to become a driving force for innovation, growth and industry consolidation in Japan, China and greater Asia." "This was a logical business step for both our companies," said Dr. Savoie, "GNI and Shanghai Genomics have been working together over a year in a successful drug development collaboration. As our work progressed, it became clear that a combined company would be better positioned to achieve our R&D and business objectives. This is but the first step of our aggressive growth strategy for becoming a major global pharmaceutical company based in Asia." "China has seen double-digit growth in the healthcare market and will become the fifth largest pharmaceutical market in the world. Combined with GNI, we are better positioned to take advantage of this historic opportunity," said Dr. Luo. About GNI Ltd. GNI Ltd. is a global pharmaceutical development group with offices in Japan, the U.K. and the United States. GNI develops therapeutic pharmaceutical products internally and in collaboration with other pharmaceutical companies through gene regulatory networks and systems pharmacology techniques based on gene regulatory network research at the University of Cambridge (Cambridge, UK), Kyushu University and the University of Tokyo in Japan. GNI's founders pioneered the use of gene regulatory network maps in microbes and in humans to identify effective pharmaceutical molecules in the genome. The Company currently has internal development programs in infectious disease, cardiovascular disease, inflammation and cancer (anti-tumor) indications. For further information please visit: http://www.gene-networks.com About Shanghai Genomics Shanghai Genomics is a Chinese biopharmaceutical company that develops novel therapeutics for the treatment of fibrosis, infectious disease, and cancer. Its integrated drug discovery platform includes signaling pathway mapping, gene expression profile studies, protein expression and purification, animal modeling, medicinal chemistry, and bioinformatics, and has enabled the rapid develop of a rich product pipeline. This month China's SFDA approved the IND for its anti-fibrosis lead compound. Drs. Ying Luo and Jun Wu, the Company's founders, received their graduate training and worked at well-known U.S. companies before returning to China to start Shanghai Genomics. The Company occupies a brand new 3,000 square meters building (one of the most modern laboratory facilities in China) located in Shanghai's prestigious Zhangjiang Hi-Tech Park. International media such as the Wall Street Journal and Forbes Magazine has covered the founding story of Shanghai Genomics. For further information please visit: http://shanghaigenomics.com/ Contact: Steven V. Yoder GET THE WORD OUT COMMUNICATIONS 537 Jones Street, #2436 San Francisco, CA 94102 415-294-4133 ph/fax www.getslightlyfamous.com Carol Cherkis, Ph.D GNI, Ltd. 560 S. Winchester Blvd. - Ste. 500 San Jose, CA 95128 Tel: 408-572-5567 Fax: 408-572-5561 www.gene-networks.com 新资投资银行与Arscientia公司（半导体行业顾问咨询公司）建立战略联盟关系Los Angeles, CA --- October, 28, 2002 NewCap Partners is pleased to announce that it has entered into a strategic alliance with Arscientia LLC, a strategic consulting firm specializing in the semiconductor and semiconductor capital equipment industries. By creating the alliance, NewCap Partners and Arscientia are combining strategic consulting and investment banking services to provide clients an expanded and valuable combination of services. "The alliance of NewCap Partners and Arscientia will allow clients to harness our diverse skills into a single capability that enables the rapid execution of strategic merger and acquisition planning coupled with the transaction expertise and the financing required to execute these plans," according to Christopher Rowan, Managing Partner of Arscientia. NewCap Partners and Arscientia believe that there will be an increasing focus on merger and acquisition transaction due to the lack of financing in the public and private equity capital markets for semiconductor and semiconductor equipment companies, and that the combination of the skills of the two organizations are a great match for clients. "The semiconductor industry is one on which we are focused, and our relationship with Arscientia allows us to couple our finance and investment banking skills with the strategic planning, industry and product knowledge of Arscientia. Christopher Rowan has a distinguished career in the semiconductor sector, and we are very please to have the opportunity to work with him," said Thomas W. Turney, Managing Principal of NewCap Partners. For Arscientia's white paper presentation that explains a new methodology for strategic planning "The Strategy of Strategy", e-mail your request to strategy@arscientia.info or contact Chris Rowan. About NewCap Partners, Inc. NewCap Partners, Inc., founded in 1987, is a private investment banking firm located in Los Angeles, California, (USA) with offices in Orange County and Silicon Valley. NewCap Partners is a "broker-dealer" registered with the U.S. Securities and Exchange Commission (SEC) and the National Association of Securities Dealers (NASD). NewCap Partners provides specialized strategic merger, acquisition and divestiture services to buyers and sellers. NewCap Partners also privately places debt and equity securities for its clients to finance expansion, acquisitions, buyouts, recapitalizations and reorganizations. NewCap Partners also specializes in business transactions in the Greater China Region. NewCap Partners is staffed by a team of senior, experienced and professional investment bankers. For additional information on NewCap Partners visit our website at www.newcap.com. About Arscientia LLC Arscientia LLC is a firm dedicated to strategic planning. Arscientia's customized programs create profitable growth for high technology companies by facilitating strategic planning and capturing emerging opportunities through the use of the Consistency of Purpose (COP) methodology. The patent pending COP methodology's unique structure and analytical and decision-making tools bring the strategic planning process from an abstract exercise to one where facts and execution are paramount.
CONTACTS: Christopher Rowan 新资投资银行与BioInfoStrategies（生命科学行业顾问咨询公司）建立战略联盟关系November 4, 2002 - Los Angeles, CA - NewCap Partners Inc., a Los Angeles based investment banking firm, announced today that it has entered into a strategic alliance with BioInfoStrategies LLC to focus on companies in the life sciences industry. BioInfoStrategies provides strategic consulting services to life science companies focused on drug discovery, molecular diagnostics, bioinformatics, and bioinstrumentation/reagents. With the alliance, NewCap Partners and BioInfoStrategies are combining strategic consulting skills and investment banking skills to provide clients with a unique combination of services. "Our combined skills will allow our clients to harness our diverse skills into a single capability that will facilitate the rapid execution of strategic merger and acquisition transactions coupled with the financing requirements that accompany them" according to Carol Cherkis, Ph.D, President of BioInfoStrategies. NewCap Partners and BioInfoStrategies believe that there will be an increasing focus on merger and acquisition transactions in the foreseeable future due to the lack of financing in the public and private equity capital markets for life sciences companies, and that the combination of the skills of the two organizations are a great match for clients. "Life sciences is one of the industries on which we are focused and our relationship with BioInfoStrategies allows us to couple our finance and investment banking skills with the industry knowledge and strategic knowledge of BioInfoStrategies. Dr. Cherkis has a distinguished career in the life sciences sector, and we are very pleased to have the opportunity to work with her." said Thomas W. Turney, Managing Principal of NewCap Partners. About NewCap Partners, Inc. NewCap Partners, Inc., founded in 1987, is a private investment banking firm located in Los Angeles, California, (USA) with offices in Orange County and Silicon Valley. NewCap Partners is a "broker-dealer" registered with the U.S. Securities and Exchange Commission (SEC) and the National Association of Securities Dealers (NASD). NewCap Partners provides specialized strategic merger, acquisition and divestiture services to buyers and sellers. NewCap Partners also privately places debt and equity securities for its clients to finance expansion, acquisitions, buyouts, recapitalizations and reorganizations. NewCap Partners also specializes in business transactions in the Greater China Region. NewCap Partners is staffed by a team of senior, experienced and professional investment bankers. For additional information on NewCap Partners visit our website at www.newcap.com. About BioInfoStrategies LLC Founded by Carol Cherkis, Ph.D, in 1996, BioInfoStrategies specializes in gathering and analyzing market and technical information to provide customized support to clients in the fields of genomics, proteomics, bioinformatics, biosensors, molecular diagnostics, and microfluidics. BioInfoStrategies's services include strategic consulting with emphasis on validating business models and assumptions, competitive analysis and tracking, pricing strategies, and marketing and sales strategies. For additional information on BioInfoStrategies visit the website at www.bioinfostrategies.com. CONTACTS:
新资投资银行与日盛嘉富投资银行建立战略联盟关系October 12, 2002 - Los Angeles, CA - NewCap Partners, Inc, a Los Angeles based investment banking firm, announced that it has entered into a strategic relationship with JS Cresvale International, an investment banking firm headquartered in Hong Kong, and its affiliate office in Shanghai, China. The two firms will jointly focus on trans-border merger and acquisition transactions, primarily between US companies and companies in China, Hong Kong, and Taiwan. NewCap Partners has been focused on corporate finance transaction in the Greater China Region which encompasses China, Hong Kong and Taiwan since 1991. NewCap Partners has been advising US companies on identifying and consummating M&A, joint venture, and investment opportunities in China since 1991. According to David Kuo, a Principal at NewCap Partners, "China has gone through an amazing transformation over the past several years and as a result of China's WTO accession we expect there to be a dramatic increase in activity between companies in the US and companies in China. We expect there to be a large number of trans-border merger and acquisition transactions as US companies take advantage of China's low-cost manufacturing base and its large potential markets. Our relationship with JS Cresvale's research resources in China, Hong Kong, Taiwan, will allow us to better serve our clients who want to take advantage of these opportunities." "This relationship with NewCap Partners will enhance our reach and contacts in the United States, particularly in California. We are happy to be able to harness the combines skills of our firms to benefit our clients both in the US and in China", commented Billy Cheng, the Chief Representative of the JS Cresvale Shanghai Office. About NewCap Partners, Inc. NewCap Partners, Inc., founded in 1987, is a private investment banking firm located in Los Angeles, California, (USA) with offices in Orange County and Silicon Valley. NewCap Partners is a "broker-dealer" registered with the U.S. Securities and Exchange Commission (SEC) and the National Association of Securities Dealers (NASD). NewCap Partners provides specialized strategic merger, acquisition and divestiture services to buyers and sellers. NewCap Partners also privately places debt and equity securities for its clients to finance expansion, acquisitions, buyouts, recapitalizations and reorganizations. NewCap Partners also specializes in business transactions in the Greater China Region. NewCap Partners is staffed by a team of senior, experienced and professional investment bankers. For additional information on NewCap Partners visit our website at www.newcap.com About JS Cresvale International Ltd. JS Cresvale is an international financial services company. Headquartered in Hong Kong, it was established in November 1999 following the purchase of the boutique Asian equity house, Cresvale Hong Kong, by Jih Sun Securities Co Ltd in Taiwan. JS Cresvale offer equity sales, asset management, research and investment banking services to institutional investors and corporations. JS Cresvale is owned by Jih Sun Securites Co Ltd. ("Jih Sun") which was founded in Taiwan in 1961. Jih Sun provides a full range of investment banking and brokerage services and is the second largest broker in Taiwan ranked by its share of stock market turnover. For additional information on JS Cresvale visit the website at www.jscresvale.com.hk CONTACTS:
|